Trial Profile
DETECT IV - A Multicenter Single Arm Phase II Study to Investigate the Clinical Efficacy of Everolimus in Combination With Endocrine Therapy in Postmenopausal Patients With Hormone-receptor Positive, HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Everolimus (Primary) ; Ribociclib (Primary) ; Anastrozole; Exemestane; Fulvestrant; Letrozole; Tamoxifen
- Indications Advanced breast cancer; HER2 negative breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms DETECT-IV
- 27 Jul 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
- 27 Jul 2022 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2024.
- 27 Jul 2022 Status changed from completed to active, no longer recruiting.